Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Amylyx Pharmaceuticals

8 clinical trials

Clinical trial
A Phase II Study of Safety and Efficacy of AMX0035 in Adult Patients With Wolfram Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-07-17
Clinical trial
A Phase 3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
An Intermediate Size, Expanded Access Protocol to Provide AMX0035, a Fixed Combination of Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO), for the Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Clinical trial
AMX0035 for Amyotrophic Lateral Sclerosis - Compassionate Use Protocol
Status: Completed, Estimated PCD: 2022-12-30
Clinical trial
A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS
Status: Active (not recruiting), Estimated PCD: 2022-05-11
Clinical trial
A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants With Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)
Status: , Estimated PCD: 2026-03-01
Clinical trial
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Completed, Estimated PCD: 2019-09-25